secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001193125-24-195400
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal reports Q2 2024 net sales of $14.6M from Rezdiffra launch; cash $1.1B
------------------------------------------------------------------------------

- Rezdiffra U.S. launch generated $14.6M net sales in Q2 2024; no product sales in prior-year period.
- Coverage in place for >50% of commercial lives; <5% of covered lives require biopsy.
- EMA decision on resmetirom MAA expected mid-2025; plans to directly commercialize in Europe.
- Q2 operating expenses $177.2M vs $86.5M YoY; SG&A drove increase on launch activities.
- Cash, equivalents and marketable securities $1.1B vs $634.1M at Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524195400/0001193125-24-195400-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312524195400/d813823d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-195400

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer